Ubiquigent appoints Dr Xavier Jacq to Scientific Advisory Board

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced

Acid discovery raises hopes of improved immunotherapies

The acidity of tumours impairs the effectiveness of anti-cancer therapies, according to a University of Dundee study that could lead to a new generation of immunotherapy treatments.